YNBY International Limited: Poll Results of Special General Meeting – All Resolutions Passed

Key Points from the Announcement

• YNBY International Limited held a Special General Meeting (SGM) on 5 June 2026.
• All proposed resolutions were approved by shareholders by way of poll.
• The primary focus was the approval, confirmation, and ratification of the 2026 Framework Agreement with Yunnan Baiyao Group Co., Ltd., including the annual caps for transactions between the parties.
• 474,710,000 votes were cast in favour of the resolutions, with zero votes against, representing full support from eligible shareholders present.
• Key executive and independent non-executive directors attended the SGM.
• No shareholders (other than certain related parties) were required to abstain or voted against the proposed resolutions.

Details of the Resolutions Passed

1. Approval of 2026 Framework Agreement:
   • The agreement was entered into on 18 March 2026 between YNBY International Limited and Yunnan Baiyao Group Co., Ltd.
   • The agreement covers the scope and annual caps for related transactions between the two companies for the coming years.
   • This ratification provides further business certainty and alignment between YNBY International and its major partner, Yunnan Baiyao Group.
2. Authorisation of Directors:
   • The company’s directors are authorised to execute all necessary documents and take all steps required to implement and give effect to the 2026 Framework Agreement.
   • This ensures that the board has the flexibility and mandate to proceed efficiently with the implementation of the agreement and related transactions.

Key Shareholder and Price-Sensitive Information

• The 2026 Framework Agreement with Yunnan Baiyao Group Co., Ltd. is a critical strategic arrangement that may have a material impact on the company’s future operations and revenue streams.
• The overwhelming approval (100% of votes cast) signals strong shareholder support, enhancing management’s mandate and the company’s alignment with its largest business partners.
• The successful passage of these resolutions removes uncertainty around the company’s business framework with Yunnan Baiyao Group, which could be price sensitive and supportive of share value.
• No shareholders (other than specified interested parties) were required to abstain from voting, and there were no votes against, indicating broad-based support and no apparent shareholder dissent.

Other Notable Information

• As of 5 June 2026, the company had 9,537,898,656 issued shares eligible to vote.
• Computershare Hong Kong Investor Services Limited acted as scrutineer for the poll.
• Directors present at the meeting included Mr. Tang Ming (Executive Director and CEO), Mr. Liu Huaiyu (Executive Director), and Mr. Wong Hin Wing (Independent Non-Executive Director).
• The board’s composition was also disclosed, listing all executive, non-executive, and independent non-executive directors.

Potential Impact on Share Price

The ratification of a significant framework agreement with Yunnan Baiyao Group, and the overwhelming shareholder support for the resolutions, are both material developments that may positively impact investor sentiment and the company’s share price. The certainty and continuity provided by these approvals support the company’s strategic direction and operational stability.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research or consult with professional advisors before making investment decisions.

YNBY 國際有限公司特別股東大會投票結果 – 全部議案獲通過

重點摘要

• YNBY 國際有限公司於 2026 年 6 月 5 日召開特別股東大會（SGM）。
• 所有提呈的決議案均獲股東以投票方式通過。
• 重點議案包括批准、確認及追認與雲南白藥集團股份有限公司訂立的 2026 框架協議，以及有關交易的年度上限。
• 共有 474,710,000 票贊成，無反對票，反映出席合資格股東全數支持。
• 多位執行董事及獨立非執行董事出席大會。
• 除特定關連人士外，無其他股東須回避投票，亦無股東表示反對或棄權，反映大多數股東無異議。

詳細決議案內容

1. 批准 2026 框架協議：
   • 協議於 2026 年 3 月 18 日由公司與雲南白藥集團股份有限公司簽訂。
   • 涵蓋雙方未來數年相關交易的內容與年度上限。
   • 此舉進一步鞏固了公司與主要合作夥伴雲南白藥集團的業務協同。
2. 授權董事執行協議：
   • 授權一位或多位董事代表公司簽署所有相關文件及執行所需事項，以落實及推行 2026 框架協議及相關事宜。
   • 確保董事會有靈活及明確授權，推動協議執行及相關交易。

重要及或影響股價的資訊

• 與雲南白藥集團簽訂的 2026 框架協議屬策略性安排，或對公司未來營運及收入有重大影響。
• 決議案獲 100% 贊成，反映股東對管理層及業務方向高度支持，有利公司穩定發展。
• 協議獲通過消除了與雲南白藥集團合作框架的不確定性，屬潛在影響股價的敏感資訊。
• 除指定關連方外，沒有股東須回避或表示反對，反映支持度極高。

其他重要資訊

• 截至 2026 年 6 月 5 日，公司已發行股份為 9,537,898,656 股，均有資格投票。
• 香港中央證券登記有限公司擔任點票監察人。
• 出席董事包括執行董事兼行政總裁唐明先生、執行董事劉懷宇先生及獨立非執行董事黃顯榮先生。
• 董事會成員名單亦有披露，包括所有執行、非執行及獨立非執行董事。

對股價的潛在影響

重點協議獲壓倒性通過，消除不穩定因素，對投資者信心及公司股價或有正面支持作用。

免責聲明

本文僅供參考，並不構成任何投資建議。投資者應自行研究或諮詢專業人士後作出投資決定。

View YNBY INTL Historical chart here